Dr Ananth Shankar

Dr Ananth ShankarTel: 020 3447 9950/020 2447 7075
Fax: 020 3447 9064
Email: ananth.shankar@nhs.net

University College Hospital

Children and young people's services

Professional background

Ananth Shankar is a Consultant Paediatric and Adolescent Oncologist at UCL Hospitals NHS Foundation Trust and is the Clinical Lead for Adolescent Neuro-Oncology. He specializes in adolescent neuro-oncology and nodular lymphocyte predominant Hodgkin Lymphoma [NLPHL]. He is a Honorary Senior lecturer in Paediatrics at the ICH/UCL and is a fellow of the Royal College of Paediatrics and Child Health, UK.

Teaching and Training
Ananth Shankar is an undergraduate examiner with University College London and is also a clinical and educational supervisor of paediatric oncology trainees as well as an assessor on ARCP panels for paediatric trainees

OP clinics
Dr Ananth Shankar has a Monday afternoon adolescent neuro-oncology outpatients’ clinic and a Wednesday morning general oncology outpatients' clinic at UCH.

Research interests

Functional imaging in paediatric and adolescent brain tumours; molecular genetics of nodular lymphocyte Predominant Hodgkin lymphoma


1. Whole-body MRI for staging and interim response monitoring in pediatric and adolescent Hodgkin's lymphoma; A comparison with multi-modality reference standard including 18F-FDG-PET-CT A Lati, L menezes, P humphries, S Daw, A Shankar, H Fitzke, L Clifton-Hadley, Andre Lopes, M Klusmann, S Punwani S Taylor [In press]
European Radiology

2. Variant histology nodular lymphocyte predominant Hodgkin lymphoma - a route to transformation? Szychot E, Shankar A, Haider A, Ramsay A.
Br J Haematol. 2017 Apr 3. doi: 10.1111/bjh.14607

3. Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups.Shankar AG, Roques G, Kirkwood AA, Lambilliotte A, Freund K, Leblanc T, Hayward J, Abbou S, Ramsay AD, Schmitt C, Gorde-Grosjean S, Pacquement H, Haouy S, Boudjemaa S, Aladjidi N, Hall GW, Landman-Parker J.
Br J Haematol. 2017 Apr;177(1):106-115. doi: 10.1111/bjh.145

4. Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma. Bulwer C, Conn R, Shankar A, Ferrau F, Kapur S, Ederies A, Korbonits M, Spoudeas HA. Clin Endocrinol, 2017 86:862-864

5. Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a report from the United Kingdom's Children's Cancer and Leukaemia Study Group.Shankar AG, Kirkwood AA, Depani S, Bianchi E, Hayward J, Ramsay AD, Hall GW.
Br J Haematol. 2016 May;173(3):421-31. doi: 10.1111/bjh.13979.

6. Childhood and Adolescent nodular lymphocyte predominant Hodgkin lymphoma - A review of clinical outcome based on the histological variants.
Shankar AG, Kirkwood AA, Hall GW, Hayward J, O'Hare P, Ramsay AD.
Br J Haematol. 2015 Jun 26. doi: 10.1111/bjh.13540

7. Evaluation of treatment response using integrated 18F-labeled choline positron emission tomography/magnetic resonance imaging in adolescents with intracranial non-germinomatous germ cell tumours. Tsouana E, Stoneham S, Fersht N, Kitchen N, Gaze M, Bomanji J, Fraioli F, Hargrave D, Shankar A.
Pediatr Blood Cancer. 2015 Sep;62(9):1661-3

8. 18F-fluoroethylcholine (18F-Cho) PET/MRI functional parameters in pediatric astrocytic brain tumors. Fraioli F, Shankar A, Hargrave D, Hyare H, Gaze MN, Groves AM, Alongi P, Stoneham S, Michopoulou S, Syed R, Bomanji JB.
Clin Nucl Med. 2015 Jan;40(1):e40-5

9. Assessing therapy response of secreting pineal germ cell tumor on simultaneous 18F-choline PET/MRI. Panagiotidis E, Shankar A, Afaq A, Bomanji J.
Clin Nucl Med. 2014 Sep;39(9):e387-8

10. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.Shankar A, Hayward J, Kirkwood A, McCarthy K, Hewitt M, Morland B, Daw S.Br J Haematol. 2014;165:534-44

GMC/GDC number: 4380308